CardiaTec funding news – CardiaTec Raises $6.5Million in Seed Funding

Montage Ventures led the round, while previous investors Laidlaw Ventures and APEX Ventures as well as new investors including Continuum Health Ventures participated. Leading figures in the industry, including Dr. Maximilien Levesque (CEO and co-founder of Aqemia) and Naheed Kurji (CEO and founder of Cyclica and former president of Recursion), participated in the round as individual investors.

Additionally, CardiaTec has added Dr. Joseph Lehár, a former SVP of R&D Strategy at the innovative techbio business Owkin, to its scientific advisory board.

Read also - Stockholm-based Tiptapp Raises €1 Million in Funding

17 million deaths worldwide are attributed to cardiovascular disease each year. It is the leading cause of death worldwide.(1) Despite the disease's widespread occurrence, therapeutic innovation in this field has stalled, partly because of a poor understanding of the biology behind the illness.

Due to this lack of knowledge, costly and extensive clinical trials have not been translated well, which has discouraged investment and subsequent innovation in the field and left a sizable unmet need for more potent medicines.

Due to their capacity to compile and analyze enormous volumes of data—such as multi-omics data, which is obtained from the genome, proteome, epigenome, and transcriptome—that humans are unable to interpret, computational tools offer enormous potential for use in drug target research.

Raphael Peralta, CEO and co-founder of CardiaTec, commented: "Modelling complex cardiovascular disease biology across multiple omic dimensions has immense potential in unlocking new therapeutic strategies that will challenge the current standard of care. Over the last several years, I am proud of the team's relentless drive to reach important milestones and our collective ambition to tackle a tough global problem. I look forward to working with our investors to accelerate our development."

Todd Kimmel, Partner at Montage Ventures, stated: “CardiaTec' is at the forefront of a new era in cardiovascular drug discovery. Their unique combination of the world's largest multi-omics dataset from human cardiac tissues and advanced computational technology positions them to uncover novel drug targets for the world's leading cause of death. With strong pharma industry connections, a growing market need, and a proprietary data moat, CardiaTec has the potential to revolutionise how we approach and treat cardiovascular diseases.”

About CardiaTec

Founded in 2021 by Prof. Namshik Han (CTO) and two alumni, Raphael Peralta (CEO) and Thelma Zablocki (COO), who were recognized as Forbes 30 under 30 Europe, CardiaTec is a spin-out from the Han Lab at the University of Cambridge. A TechBio startup called CardiaTec uses computational techniques to unravel the biology underlying cardiovascular illness. They use extensive, high-dimensional human omics data to better understand the biology of complicated diseases and find unique, targeted treatments.